Major post-operative complications after neoadjuvant chemo-radiotherapy in stage III non small cell lung cancer

被引:0
|
作者
Granone, P [1 ]
Margaritora, S [1 ]
D'Andrilli, A [1 ]
Cesario, A [1 ]
Bonatti, PL [1 ]
Galetta, D [1 ]
Kawamukai, K [1 ]
Picciocchi, A [1 ]
机构
[1] Catholic Univ Rome, A Gemelli Hosp, Dept Gen Surg 1, Div Thorac Surg, Rome, Italy
关键词
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
The choice of neoadjuvant therapies, by now largely approved for locally advanced Non Small Cell Lung Cancers (NSCLC), is related in most authors' experience, to an increased perioperative morbidity and mortality rate. In particular a significant higher incidence of broncho-pleural fistulas (BPF) after chemo-radiotherapy (CT-RT) preoperative treatment is reported. We reviewed the records of IIIa and IIIb, NSCLC patients who have undergone neoadjuvant CT-RT to evaluate the impact on perioperative morbidity and mortality. From 1/1/'90 to 30/6/'96 we have operated 47 patients (36 ma and 11 mb) over 91 who were enrolled in the neoadjuvant protocol study (Carboplatin 90 mg/mq/day from day 1 to 4 with concurrent radiotherapy on the tumour and the mediastinum with a daily fraction dose of 180 cGy from day 1 to 28 and a total administation dose of 5040 cGy). We reported a major complication in 3 patients (6,4%). These include a BPF in 2 cases and one case of pneumonia in a patient deceased after right pneumonectomy. Complications incidence was higher in patients who underwent pneumonectomy (15,3%) compared to those who underwent lesser resections lobectomy, bilobectomy, wedge) (3%). This difference is not statistically significant. In our experience neoadjuvant CT-RT for locally advanced NSCLC has been, generally, well tolerated and it wasn't complicated by a post-operative morbidity and mortality increased rate.
引用
收藏
页码:387 / 391
页数:5
相关论文
共 50 条
  • [21] Recurrence pattern and its prognostic impact following definitive chemo-radiotherapy in stage III non-small cell lung cancer
    Saigi Morgui, M.
    Rullan Iriarte, A. J.
    Bergamino, M.
    Navarro, A.
    Arnaiz, M. M.
    Palmero, R.
    Plana Serrahima, M.
    Mesia, C.
    Padrones, S.
    Aso, S.
    Ruffinelli Rodriguez, J.
    Navarro, V.
    Brao, I.
    Nadal, E.
    Cardenal Alemany, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Mutation Profile Prognostic Value in Stage III Non Small Cell Lung Cancer (NSCLC) Patients Treated with Chemo-Radiotherapy (CRT)
    Boros, Angela
    Lacroix, Ludovic
    Lancas, Benjamin
    Adam, Julien
    Pignon, Jean-Pierre
    Caramella, Caroline
    Planchard, David
    Levy, Antonin
    De Montpreville, Vincent
    Deutsch, Eric
    Besse, Benjamin
    Le Pechoux, Cecile
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S288 - S288
  • [23] Post-operative radiotherapy (PORT) in patients with resected non small cell lung cancer (NSCLC)
    Schimek-Jasch, T.
    Kuppler, M.
    Adebahr, S.
    Grosu, A. L.
    Nestle, U.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S663 - S664
  • [24] Vinorelbine-based chemo-radiotherapy in non-small cell lung cancer
    Scotti, Vieri
    Saieva, Calogero
    Di Cataldo, Vanessa
    Bruni, Alessio
    Desideri, Isacco
    Bertocci, Silvia
    Meattini, Icro
    Livi, Lorenzo
    Simontacchi, Gabriele
    Cardillo, Carla De Luca
    Bendinelli, Benedetta
    Bastiani, Paolo
    Mangoni, Monica
    Agresti, Benedetta
    Biti, Giampaolo
    TUMORI, 2012, 98 (04) : 464 - 470
  • [25] Use of chemo-radiotherapy in locally advanced non-small cell lung cancer
    Novello, S
    Le Chevalier, T
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (02) : 292 - 299
  • [26] Optimal chemotherapy regimen for concurrent chemo-radiotherapy of locally advanced unresectable stage III non-small cell lung cancer (NCSLC)
    Jokhadze, N.
    Kiladze, I.
    Katselashvili, L.
    Kacharava, M.
    Jankarashvili, N.
    Zumbadze, I.
    Kalandarishvili, N.
    Melkadze, T.
    Gogua, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S66 - S67
  • [27] Predictors of Relapse and Evaluation of Post-Operative Radiotherapy in Patients with Resected Stage III (N2) Non-Small Cell Lung Cancer
    Breen, William
    Merrell, Kenneth
    Mansfield, Aaron
    Wigle, Dennis
    Garces, Yolanda
    Olivier, Kenneth
    Hallemeier, Christopher
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S574 - S574
  • [28] Pleural effusion in patients receiving definitive chemo-radiotherapy followed by durvalumab immunotherapy for stage III non-small cell lung cancer
    Yong, Wee Siang
    Nguyen, Thu
    Roberts-Thomson, Rachel
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 50 - 51
  • [29] Efficacy of Chemo-Radiotherapy (CRT) in Stage III Non-Small Cell Lung Cancer (NSCLC) and PD-L1 Expression
    Adam, Julien
    Boros, Angela
    Lacas, Benjamin
    Lacroix, Ludovic
    Pignon, Jean-Pierre
    Caramella, Caroline
    Planchard, David
    Levy, Antonin
    Besse, Benjamin
    Le Pechoux, Cecile
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S244 - S244
  • [30] The impact of radiotherapy for post-operative patients with stage II or stage III non-small cell lung cancer utilizing the surveillance, epidemiology, and end results database
    Lally, BE
    Wilson, LD
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S102 - S103